<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02968355</url>
  </required_header>
  <id_info>
    <org_study_id>SDY-017266</org_study_id>
    <secondary_id>HHSN272201600002C</secondary_id>
    <secondary_id>W911QY-13-D-0080</secondary_id>
    <nct_id>NCT02968355</nct_id>
  </id_info>
  <brief_title>Clinical Evaluation of the FilmArray® Global Fever (GF) Panel</brief_title>
  <official_title>Clinical Evaluation of the FilmArray® Global Fever (GF) Panel</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>BioFire Defense LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>United States Department of Defense</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>BioFire Defense LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the clinical sensitivity and specificity of the FilmArray Global&#xD;
      Fever (GF) Panel.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The FilmArray Global Fever (GF) Panel, developed by BioFire Defense in collaboration with the&#xD;
      U.S. Department of Defense and NIAID, uses an automated, multiplex PCR system to evaluate&#xD;
      whole blood samples for 19 pathogens simultaneously in under an hour. Targets of the GF Panel&#xD;
      are Chikungunya virus, CCHF virus, dengue virus (serotypes 1-4), Ebolavirus, Lassa virus,&#xD;
      Marburgvirus, West Nile virus, Yellow fever virus, Zika virus, Bacillus anthracis,&#xD;
      Francisella tularensis, Leptospira spp., Salmonella enterica serovar Typhi and Paratyphi A,&#xD;
      Yersinia pestis, Leishmania donovani complex, Plasmodium spp., P. falciparum, and P.&#xD;
      ovale/vivax. BioFire Defense is conducting a prospective clinical study to evaluate the&#xD;
      sensitivity and specificity of the GF Panel when used to test blood collected from subjects&#xD;
      with fever or who have recently had fever. This multi-center study is being conducted at&#xD;
      locations around the world.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">March 26, 2018</start_date>
  <completion_date type="Anticipated">June 2022</completion_date>
  <primary_completion_date type="Actual">March 30, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical sensitivity and specificity of the FilmArray Global Fever (GF) Panel</measure>
    <time_frame>18 months</time_frame>
    <description>Percent Positive Agreement and Percent Negative Agreement between FilmArray Result and Comparator Assay</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">2084</enrollment>
  <condition>Fever</condition>
  <arm_group>
    <arm_group_label>Subjects/Specimens</arm_group_label>
    <description>Subjects/Specimens that meet the eligibility criteria</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Observational study</intervention_name>
    <description>Observational study</description>
    <arm_group_label>Subjects/Specimens</arm_group_label>
    <other_name>FilmArray</other_name>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Whole blood specimen may be retained at the participating clinical sites for future use.&#xD;
      Specimen nucleic acid may be retained at BioFire and participating clinical sites for future&#xD;
      performance evaluations of the FilmArray.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Subjects with fever will be prospectively enrolled, and whole blood will be collected.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Whole blood in EDTA (prospectively collected via informed consent)&#xD;
&#xD;
          -  Subject has a recorded or self-reported fever within the past two days.&#xD;
&#xD;
          -  Subject has not participated in the study within the last 30 days.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Cynthia Phillips, Ph. D.</last_name>
    <role>Study Director</role>
    <affiliation>BioFire Defense LLC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>George Washington University</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20037</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Naval Medical Research Unit Two</name>
      <address>
        <city>Phnom Penh</city>
        <country>Cambodia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>United States Army Medical Research Directorate Georgia</name>
      <address>
        <city>Tbilisi</city>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Naval Medical Research Unit Three</name>
      <address>
        <city>Navrongo</city>
        <country>Ghana</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universidad Nacional Autonoma de Honduras</name>
      <address>
        <city>Tegucigalpa</city>
        <state>Central District</state>
        <country>Honduras</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>United States Army Medical Research Directorate Kenya</name>
      <address>
        <city>Kisumu</city>
        <country>Kenya</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Naval Medical Research Unit Six</name>
      <address>
        <city>Iquitos</city>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kilimanjaro Christian Medical Centre</name>
      <address>
        <city>Moshi</city>
        <country>Tanzania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Armed Forces Research Institute of Medical Sciences</name>
      <address>
        <city>Bangkok</city>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Infectious Diseases Institute</name>
      <address>
        <city>Kampala</city>
        <country>Uganda</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Cambodia</country>
    <country>Georgia</country>
    <country>Ghana</country>
    <country>Honduras</country>
    <country>Kenya</country>
    <country>Peru</country>
    <country>Tanzania</country>
    <country>Thailand</country>
    <country>Uganda</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>India</country>
  </removed_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 16, 2016</study_first_submitted>
  <study_first_submitted_qc>November 16, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 18, 2016</study_first_posted>
  <last_update_submitted>November 16, 2021</last_update_submitted>
  <last_update_submitted_qc>November 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fever</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>IPD will not be shared with other researchers.</ipd_description>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>March 22, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/55/NCT02968355/ICF_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

